Nyxoah SA is a medical technology company. It focused on the development and commercialization of solutions to treat Obstructive Sleep Apnea. Nyxoah SA is based in Belgium.
| Revenue (Most Recent Fiscal Year) | $4.89M |
| Net Income (Most Recent Fiscal Year) | $-64.10M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 28.44 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.84 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1508.78% |
| Net Margin (Trailing 12 Months) | -1541.84% |
| Return on Equity (Trailing 12 Months) | -79.18% |
| Return on Assets (Trailing 12 Months) | -54.92% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.63 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.38 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.29 |
| Inventory Turnover (Trailing 12 Months) | 0.34 |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.60 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.63 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.96 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.30 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Common Shares Outstanding | 34.06M |
| Free Float | 28.23M |
| Market Capitalization | $152.93M |
| Average Volume (Last 20 Days) | 0.06M |
| Beta (Past 60 Months) | 1.60 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 17.11% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |